Photronics, Inc. — Q2 FY2023 Form 10-Q
Reporting period: Three and six months ended April 30, 2023; comparisons are against the three and six months ended May 1, 2022, unless noted. Photronics manufactures photomasks for integrated circuits (IC) and flat-panel displays (FPD). Amounts below are in U.S. dollars; financial statement amounts are generally converted to millions.
Key financial results
| Metric | Q2 FY2023 | Q2 FY2022 | Six months FY2023 | Six months FY2022 |
|---|---|---|---|---|
| Revenue | $229.3m | $204.5m | $440.4m | $394.3m |
| Gross profit / margin | $88.4m / 38.6% | $70.2m / 34.3% | $164.5m / 37.3% | $130.1m / 33.0% |
| Operating income | $67.0m | $49.4m | $123.0m | $87.6m |
| Net income | $59.3m | $43.0m | $88.2m | $74.8m |
| Net income attributable to Photronics shareholders | $39.9m | $27.4m | $53.9m | $50.5m |
| Diluted EPS | $0.65 | $0.45 | $0.88 | $0.83 |
Q2 revenue rose 12.1% year over year and 8.6% from Q1 FY2023. Q2 gross margin was 38.6%, versus 36.0% in Q1. Six-month operating cash flow was $109.7m, compared with $103.3m. Capital spending was $57.7m, up from $34.8m; reported free cash flow, a non-GAAP measure, was $52.0m versus $68.5m.
Balance sheet and liquidity
- At April 30, 2023, cash and cash equivalents were $367.5m and short-term investments were $45.4m. Cash and cash equivalents included $352.4m held by foreign subsidiaries.
- Total debt was $28.3m, comprising finance leases; the Xiamen project loans were fully repaid during Q2. The company had no borrowings under its corporate credit agreement. Non-GAAP net cash was approximately $339m.
- Current assets were $720.1m and current liabilities were $185.2m. Total assets were $1.45bn.
- Six-month investing cash outflow was $62.3m; financing cash outflow was $15.2m. Cash increased by $47.8m, including a favorable $15.6m foreign-exchange effect.
Material changes and management commentary
- IC revenue increased 14.6% year over year in Q2, led by mainstream masks; high-end IC revenue declined 14.5%. Management cited strong Asian demand, increased pricing, and constrained mainstream tool capacity. Expediting premiums declined.
- FPD revenue increased 6.0% year over year, as high-end AMOLED-related demand more than offset weakness in mainstream FPD. Management expects demand for high-end AMOLED photomasks to continue, but this is commentary, not quantified guidance.
- Six-month revenue increased 11.7% year over year. Mainstream IC growth was a major contributor; six-month FPD revenue declined 1.7%.
- Q2 included a $10.7m foreign-currency transaction gain, compared with a $7.8m gain in Q2 FY2022. For the six-month period, foreign-currency transactions produced a $6.2m loss, compared with a $13.1m gain a year earlier. These movements materially affected reported pre-tax income.
- Gross-margin improvement reflected higher revenue, favorable pricing and product mix, and volume leverage. Six-month SG&A rose $2.4m; R&D fell $3.4m, primarily due to reduced development activity in several regions.
Outlook, risks, contingencies, and unusual items
- The filing does not state numerical revenue or earnings guidance; it refers readers to the separate Q2 earnings release, presentation, and conference call. Management estimated FY2023 capital expenditures of approximately $130m, targeted mainly at IC capacity and efficiency.
- At April 30, capital-expenditure commitments were approximately $113.1m; including recognized equipment-purchase liabilities, total committed and recognized obligations were $128.6m. The company estimated $94.0m would be funded over the next 12 months.
- Management said liquidity, including available financing, should meet requirements for the next 12 months and foreseeable future. Available facilities include a $50m U.S. credit agreement, expandable to $100m, and approximately $25m of China borrowing capacity.
- Foreign-exchange risk is significant: a 10% adverse currency movement was estimated to produce a $48.0m net unrealized pre-tax loss. The largest cited exposures were the New Taiwan dollar ($21.4m), Korean won ($12.2m), and RMB ($11.4m) against the U.S. dollar.
- DNP has certain rights to put its interest in the PDMCX China joint venture to Photronics, or purchase Photronics’ interest, subject to specified conditions. DNP had not indicated an intent to exercise those rights. Each party’s net investment was approximately $110.9m.
- A China customs audit contingency was settled in November 2022; Photronics reversed $1.0m of a prior $2.2m accrual. The filing says other ordinary-course claims are not expected to have a material effect. Unrecognized tax benefits were $7.1m; management expected amounts potentially resolved over the next 12 months to be immaterial.
- Other risks include semiconductor and display design-cycle volatility, customer and industry demand changes, capacity and pricing shifts, and possible supply-chain disruption. Management reported no material change in previously disclosed risk factors.
Investor facts to verify
- Review the separate Q2 FY2023 earnings materials for the numerical guidance omitted from this 10-Q.
- Assess whether mainstream IC demand, constrained capacity, and pricing remain supportive, and whether high-end IC softness persists.
- Separate operating performance from currency-driven gains and losses; note that non-GAAP net cash and free cash flow supplement, but do not replace, GAAP measures.
- Track execution and funding of planned capital spending, including the $113.1m outstanding commitments and $128.6m total committed and recognized obligations.
- Monitor currency exposures and the PDMCX joint-venture put/purchase provisions; check the filing’s detailed terms and any subsequent developments.